title: The alpha1-adrenergic receptor antagonists, benoxathian and prazosin, induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells.
abstract: The erythroleukemia cell lines K562 and human erythroleukemia (HEL) are established models to study erythroid and megakaryocytic differentiation in vitro. In this study, we show that the alpha1-adrenergic antagonists, benoxathian and prazosin, inhibit the proliferation and induce apoptosis in K562 and HEL cells. Furthermore, both tested substances induced the expression of the megakaryocytic marker CD41a, whereas the expression of the erythroid marker glycophorin-a was decreased or unchanged. Even though the expression of differentiation markers was similar after benoxathian and prazosin treatment in both cell lines, endomitosis of erythroleukemia cells was observed only after prazosin treatment. So far, benoxathian and prazosin are the first described extracellular ligands, which cause megakaryocytic differentiation in K562 and HEL cells. In summary, these results indicate a possible role of alpha1-adrenergic receptor signaling in the regulation of erythroid and megakaryocytic differentiation, even though the receptor dependence of the observed effects needs further investigation.
authors.affiliation: Institute of Pathophysiology and Immunology, Center of Molecular Medicine, Medical University of Graz, Heinrichstrasse 31A, 8010, Graz, Austria. robert.fuchs@medunigraz.at
authors.forename: Robert
authors.initials: R
authors.lastname: Fuchs
authors.forename: Ingeborg
authors.initials: I
authors.lastname: Stelzer
authors.forename: Helga S
authors.initials: HS
authors.lastname: Haas
authors.forename: Gerd
authors.initials: G
authors.lastname: Leitinger
authors.forename: Konrad
authors.initials: K
authors.lastname: Schauenstein
authors.forename: Anton
authors.initials: A
authors.lastname: Sadjak
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects*; D045744:Cell Line, Tumor; D041905:Erythroid Cells; D006801:Humans; D020014:K562 Cells; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy* / Q000473:pathology; D008533:Megakaryocytes / Q000166:cytology*; D010075:Oxathiins / Q000494:pharmacology*; D011224:Prazosin / Q000494:pharmacology*; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*
chemical_list: D000317:Adrenergic alpha-Antagonists; D010075:Oxathiins; D018340:Receptors, Adrenergic, alpha-1; C050877:benoxathian; D011224:Prazosin